We are live on ! Find out more
CRL icon

Charles River Laboratories

339 hedge funds and large institutions have $5.16B invested in Charles River Laboratories in 2017 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 129 increasing their positions, 113 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more call options, than puts

Call options by funds: $6.01M | Put options by funds: $2.08M

14% more repeat investments, than reductions

Existing positions increased: 129 | Existing positions reduced: 113

11% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 46

3.24% more ownership

Funds ownership: 96.5%99.74% (+3.2%)

4% more capital invested

Capital invested by funds: $4.96B → $5.16B (+$201M)

1% more funds holding

Funds holding: 336339 (+3)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
339
Holders Change
+3
Holders Change %
+0.89%
% of All Funds
7.67%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
51
Increased
129
Reduced
113
Closed
46
Calls
$6.01M
Puts
$2.08M
Net Calls
+$3.93M
Net Calls Change
+$6.6M

CRL Hedge Fund Activity: Q4 2017 in Review

339 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2017, worth a combined $5.16B — up 4.1% from $4.96B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new CRL positions and 46 closed out — a net gain of 5 holders — while 129 added to existing stakes and 113 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $148M. The largest seller was Morgan Stanley, cutting an estimated $87.6M.

  • 339 institutional investors held Charles River Laboratories (CRL) as of Q4 2017, up from 336 in Q3 2017.
  • Funds reported $5.16B of Charles River Laboratories stock for Q4 2017, up 4.1% quarter-over-quarter.
  • 51 funds opened new Charles River Laboratories positions in Q4 2017 and 46 closed out, a net change of +5 holders.
  • The largest Charles River Laboratories buyer in Q4 2017 was William Blair Investment Management, an estimated $148M added.
  • The largest Charles River Laboratories seller in Q4 2017 was Morgan Stanley, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2017.